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The pleiotrophic inflammatory cytokine, interleukin 6 (IL-6) is
emerging as a key factor involved in regulation of local oestrogen
biosynthesis in breast tumours. It achieves this by activating three
principal enzyme complexes involved in oestrogen production,
namely, aromatase, steroid sulphatase and 17-HSD type I (Speirs
et al, 1993; Reed and Purohit, 1997). Both the IL-6 gene and
protein are present in breast tumours and breast primary cultures
(Basolo et al, 1996; Green et al, 1997). Receptors for both IL-6
and its signalling component, gp130, have been detected both in
breast tumours and breast cancer cell lines (Chiu et al, 1996;
Crichton et al, 1996; Douglas et al, 1997). Although elevated
serum levels of IL-6 do not appear to affect survival in breast
cancer patients, a recent study of 60 patients has shown raised
serum IL-6 in 27% of these patients compared to only 2% of age-
matched controls (Asgeirsson et al, 1998).
Substantial clinical, epidemiological and laboratory data show
that oestrogen is a potent mitogen in breast cancer. Oestrogen
action is mediated by binding to its nuclear receptor, the ER. Once
bound to ligand, ER dimerization occurs and the resulting homo-
dimer then binds to oestrogen response elements (EREs) in the
transcriptional control region of target genes, thus initiating
transcription of oestrogen-responsive genes. Two ERs have been
identified, the classic ER, now known as ERa (Green et al, 1986;
Greene et al, 1986) and a second receptor, ERb (Mosselman et al,
1996). ERb is highly homologous to ERa, at the DNA (96%) and
ligand binding (58%) domains, while the A/B domain, hinge
region and F region are not well-conserved (Mosselman et al,
1996). Further work has indicated that in addition to homodimers,
the  a and  b receptors can form DNA-binding heterodimers
(Cowley et al, 1997; Pace et al, 1997).
As well as oestrogen-stimulated proliferation, the growth and
metabolism of breast cancer cells is additionally modulated by
growth factors/cytokines, which can be secreted under direct and
indirect regulation of 17b-oestradiol (E2; Dickson et al, 1986).
IL-6 is one such factor (Speirs et al, 1993; Duncan et al, 1994).
There is evidence for cross-talk between ERa and growth factors
with direct activation of ERa in response to IL-2 (Newton et al,
1994a) and IGF-I (Newton et al, 1994b; Lee et al, 1997) in
ERa-positive breast and pituitary cell lines. Related to these
observations, IL-6 has recently been shown to activate the
androgen receptor in another hormone-sensitive cancer, prostate
cancer (Hobisch et al, 1998).
Previously, we have shown that IL-6 strongly synergizes with
E2, leading to increases in reductive 17b-hydroxysteroid dehydro-
genase activity (and hence E2 production) in breast cancer epithe-
lial cells (Speirs et al, 1993). A recent study showed a correlation
in expression of IL-6 with ERa in breast tumours (Fontanini et al,
1999). It has also been reported that the inhibitory effects of IL-6
on breast tumour cells is dependent on ERa status: ERa+ cells
Direct activation of oestrogen receptor-a by interleukin-6
in primary cultures of breast cancer epithelial cells
V Speirs1, MJ Kerin2, DS Walton1, CJ Newton1, SB Desai3 and SL Atkin1
Departments of 1Medicine and 2Academic Surgical Unit, Medical Research Laboratory, University of Hull, Hull HU6 7RX, UK; 3Scunthorpe General Hospital,
Scunthorpe DN15 7BH, UK
Summary Interleukin 6 (IL-6) is secreted by breast tumours and shows synergistic activity with 17b-oestradiol (E2), leading to increases in
reductive 17b-hydroxysteroid dehydrogenase activity in breast cancer epithelial cells. However, the mechanisms involved are poorly
understood. Using short-term epithelial cultures established from primary breast tumours, we have examined whether IL-6 could directly
affect transcriptional activity of oestrogen reception a (ERa). Tumour epithelial cultures were established from 15 breast tumours, grown to
70% confluence and transiently transfected with a plasmid reporter containing the vitellogenin oestrogen response element and the luciferase
coding sequence (ERE-TK-LUC). Following transfection, cells were incubated with E2, IL-6, the pure anti-oestrogen ZM 182780 or
combinations of these substances for 48 h. Luciferase activity was then measured in cell lysates. E2 caused a dose-dependent increase in
luciferase expression, causing a maximum threefold stimulation at 100 pM. In the presence of IL-6, transcriptional activity was increased by
up to 2.5-fold in ERa+ cultures (11/15). In combination with E2, synergistic effects were observed with increases in luciferase activity of up to
sixfold over controls. This effect could be blocked by treatment with ZM 182780. Pre-incubation of cells with an antibody directed against the
signalling component of IL-6, gp130, was ineffective in blocking the E2 response. This antibody reduced, but did not completely block the
effect of IL-6 either alone or in combination with E2, suggesting cross-talk between the two signalling pathways. In conclusion, these results
provide evidence for direct transcriptional activation of ERa by IL-6. © 2000 Cancer Research Campaign
Keywords: breast cancer; steroids; interleukin-6
1312
Received 2 August 1999
Revised 5 November 1999
Accepted 8 November 1999
Correspondence to: V Speirs, Molecular Medicine Unit, Clinical Sciences
Building, St James’s University Hospital, Leeds LS9 7TF, UK 
British Journal of Cancer (2000) 82(7), 1312–1316
© 2000 Cancer Research Campaign
DOI: 10.1054/ bjoc.1999.1097, available online at http://www.idealibrary.com on ER activation in breast 1313
British Journal of Cancer (2000) 82(7), 1312–1316 © 2000 Cancer Research Campaign
respond to IL-6 while ERa– cells were refractory to IL-6-mediated
growth inhibition (Chiu et al, 1996). Based on these findings, we
hypothesized that IL-6 may regulate activity of ERa in breast
cancer. Therefore, the aim of the present study was to determine
whether IL-6 could directly affect transcriptional activation of
ERa using short-term primary cultures of human breast cancer
epithelial cells as an in vitro model.
METHODS
Cell culture
Breast tumours (n = 15) were acquired directly from surgery and
dispersed overnight in 0.1% collagenase type III (Life
Technologies, Paisley, UK; Speirs et al, 1996a). All tumours were
from post-menopausal patients and of ductal origin and grades 2
or 3. Eleven were positive for ERa. Ethical approval was
obtained and all patients gave informed consent. Epithelial cells
were isolated from the digest by differential centrifugation
followed by culture in selective media (Speirs et al, 1998). These
cells have previously been characterized by immunostaining,
flow cytometry and genetic analysis and those derived from ERa+
tumours retain functional ER in vitro (Speirs et al, 1996b, 1998).
Because of the reported weak oestrogenic effects of phenol red
indicator found in standard tissue culture medium (Berthois et al,
1986), cultures were established in phenol red-free medium
supplemented with 100 U ml–1 penicillin, 100 mg ml–1 strepto-
mycin, 2 mM glutamine, 10 mM HEPES, 0.075% bovine serum
albumin (BSA) (all Life Technologies), 10 ng ml–1 cholera toxin
(ICN Biomedicals, Oxon, UK), 0.5 mg ml–1 hydrocortisone, 5 mg
ml–1 insulin and 5 ng ml–1 epidermal growth factor (EGF) (all
Sigma, Poole, UK). All subsequent experiments were conducted
in this medium.
Transient transfection
Freshly isolated epithelial cells were grown to 70% confluence
(achieved after 3–5 days in vitro) in 6-well plates and transiently
co-transfected using the cationic lipid, Lipofectamine (Life
Technologies), with 5 mg of pSV b-galactosidase plasmid
(Promega, Southampton, UK) and a plasmid reporter containing
the vitellogenin ERE and the luciferase coding sequence (ERE-
TK-LUC; Meyer et al, 1994) for 4 h at 37°C. Transfected cells
were then incubated with either E2, IL-6 (10 ng ml–1; Genzyme,
West Malling, UK), the pure anti-oestrogen ZM 182780 (10 nM),
anti-gp130 antibody (R&D Systems, Oxford, UK) or combina-
tions of these substances. Appropriate positive (MCF-7 cells
stably transfected with ERE-TK-LUC) and negative controls
(primary cultures transiently transfected with a plasmid lacking
the ERE) were set up in parallel. After 48 h, cultures were lysed
and luciferase and b-galactosidase activities were measured.
Luciferase activity was determined using a Report-a-Gene kit
(Labtech International, Uckfield, UK) according to the manufac-
turer’s instructions and quantified in a luminometer (Labtech
International).  b-galactosidase activity was measured by spectro-
photometry at 420 nm. For each sample, luciferase activity was
corrected for b-galactosidase activity and the final result expressed
as percentage of untreated control. All experiments were repeated
in triplicate.
ELISA
Levels of IL-6sR were quantitatively determined in conditioned
medium (CM) by sandwich enzyme-linked immunosorbent assay
(ELISA) (Boehringer Mannheim, East Lewes, UK). Breast cancer
epithelial cultures from ten breast tumours were grown to 70%
confluence, then incubated for 72 h with serum-free medium. CM
was collected, centrifuged at 1000 rpm for 5 min to remove any
particulate matter and stored at –80°C until analysed according to
the manufacturer’s instructions. The intra- and inter-assay vari-
ances were < 6% and < 12% respectively, with a sensitivity of
20 pg ml–1 and the assay was not influenced by IL-6 up to
500 ng ml–1. To correct for differences in growth rates of cultures
established from different tumours, cultures from which the CM
was collected were trypsinized and counted and the OD reading
obtained for IL-6sR divided by cell number.
Statistical analysis
All experiments were repeated in triplicate. Statistical analysis
was performed using the Arcus software package for Windows
(Research Solution, Cambridge, UK) on pooled data from indi-
vidual cultures. The two-tailed Mann–Whitney U-test was used to
test the difference between groups. Results were considered to be
significant at P ≤ 0.05.
RESULTS
Steroidal activation of ERa
Addition of E2 to ERa+ breast cancer epithelial cells transfected
with an ERE linked to a luciferase reporter gene caused a dose-
dependent increase in luciferase activity. A maximum threefold
stimulation was observed at 100 pM (Figure 1). This is consistent
with activation of ERa. To determine whether ERa was directly
involved in increasing transcriptional activity, parallel cultures
were incubated with the pure anti-oestrogen ZM 182780, which
acts as an oestrogen antagonist. This completely abrogated the
effects of E2 (Figure 1). No effects of E2 or anti-oestrogen were
observed when similar cultures were transfected with a plasmid
vector lacking the ERE, confirming the specificity of E2 for the
response element.
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Figure 1 Effect of increasing concentrations of 17b-oestradiol on luciferase
activity in breast cancer epithelial cells and its antagonism by ZM 182780.
ns DNA = plasmid lacking the ERE reporter. Each data point represents the
mean + s.e.m. *P < 0.05, **P < 0.002 vs. control (Ctrl)1314 V Speirs et al
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Activation of ERa by IL-6 and the effect of anti-gp130
Transcriptional activation of ERa was also observed in response to
IL-6 (10 ng ml–1), although the effect was much more modest,
typically about two-thirds of the E2 response (Figure 2). No
further increases in transcriptional activity in response to IL-6
were observed by increasing the concentration of this cytokine to a
maximum of 25 ng ml–1 (data not shown). As shown in Figure 2,
when E2 (100 pM) and IL-6 (10 ng ml–1) were added in combina-
tion, additive effects were observed with a sixfold increase in tran-
scriptional activity. Addition of ZM 182780 significantly reduced
the additive effects observed when E2 was combined with IL-6.
Pre-incubation of cells with an antibody directed against gp130
was ineffective in blocking the E2 response and reduced but did
not completely block the effect observed with IL-6 alone or in
combination with E2 (Figure 3).
Production of IL-6sR by breast cancer epithelial cells
A soluble form of the IL-6 receptor, IL-6sR, has been described
which in contrast to other known cytokine soluble receptors,
enhances the response of IL-6 in some biological systems
(Mackiewicz et al, 1995). Therefore, IL-6sR was measured in CM
samples collected from the epithelial cultures. IL-6sR was
detected in all cultures, which produced a mean 41.12 pg ml–1
IL-6sR (equivalent to 26.6 pg ml–1 10–6 cells; range 9.1–50.4).
Although no statistically significant differences in production of
IL-6sR were observed between ERa+ and ERa– cultures, there was
a suggestion of a trend for increased IL-6sR production by those
which were ERa+.
DISCUSSION
Using short-term primary cultures of breast cancer epithelial cells
transiently transfected with the ERE-TK-LUC reporter plasmid as
an in vitro model, this study has identified IL-6 as an activator of
human ERa at the level of gene transcription. Further, although
the signalling pathway of IL-6 is divergent from that of E2, this
cytokine showed additive effects on transcriptional activity when
combined with steroid. Our results complement and extend our
previous work, which demonstrated additive/synergistic effects
between IL-6 and E2 in regulating the reductive pathway of the
steroid converting enzyme, 17-HSD type I (Speirs et al, 1993), and
an association of IL-6 with other enzymes involved in modulating
local oestrogen biosynthesis (Speirs et al, 1999).
As predicted, transcriptional activation of ERa was observed in
response to E2. This was only observed in ERa+ cultures (11/15),
indicating the requirement of ligand bound receptor to interact
with the ERE. An increase in transcriptional activity from the same
reporter was also observed in response to IL-6, although typically
only about two-thirds of the levels observed with E2 were
achieved. Again this was only evident in ERa+ cells. When IL-6
and E2 were co-incubated, additive/synergistic effects were
observed. To determine if this was modulated via ERa, two exper-
imental approaches were undertaken. First, the pure anti-oestrogen
ZM 182370 was added as an antagonist to E2. Incubation with ZM
182370 blocked the effect of E2, either alone or when combined
with IL-6. Unexpectedly, the anti-oestrogen also blocked the
stimulatory effect of IL-6 added alone, suggesting that the effect of
IL-6 may be independent of its receptor. To address this, the
signalling component of the IL-6 receptor, gp130, was blocked
using specific antibodies. The IL-6 receptor consists of an 80 kDa
ligand-binding domain (gp80) and a 130 kDa signal-transducing
protein (gp130) which lacks IL-6 binding activity. Association of
ligand-bound gp80 with gp130 is necessary for signal transduction
which is mediated by tyrosine kinases of the janus kinase family
(Jaks) and STAT transcription factors (Kishimoto et al, 1992).
When the IL-6 receptor was blocked with anti-gp130 antibodies
the effect of IL-6 on transcriptional activity was inhibited; this had
no effect on transcriptional activity of E2. The antibody also
reduced, but did not completely block the cumulative effect of
IL-6 and E2. Although the residual activity was less than that
observed with E2 alone, this is probably mediated by E2 rather
than IL-6 as blocking the gp130 signal transducer would prevent
the formation of gp130 homodimers necessary for IL-6 signalling.
The presence of mRNA and protein for the complete IL-6
signalling system, i.e. peptide and gp80/gp130 receptors has been
shown previously in human breast cancer biopsies (Crichton et al,
1996; Douglas et al, 1997; Green et al, 1997). A 55 kDa soluble
form of gp80, known as IL-6sR, also exists. This is found in
serum, is released into culture medium by the breast cancer cell
line, MCF-7 and can be regulated by steroids and cytokines,
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Figure 2 Representative graph illustrating the mean effects + s.e.m. of E2
(100 pM) and IL-6 (10 ng ml–1) alone or in combination and the antagonistic
effects of ZM 182780 (10 nM) on luciferase activity in breast cancer epithelial
cells. ns DNA = plasmid lacking the ERE reporter. *P < 0.002, **P < 0.05 vs.
control (Ctrl)
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Figure 3 Effects (mean + s.e.m.) of gp130 alone or in combination with E2
(100 pM) ± IL-6 (10 ng ml–1) on luciferase activity in breast cancer epithelial
cells. ns DNA = plasmid lacking the ERE reporter. *P < 0.05, **P <0.002 vs.
control (Ctrl)ER activation in breast 1315
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including IL-6 (Singh et al, 1995). By ELISA, we showed IL-6sR
was also produced by our primary cultures. IL-6 can bind to
IL-6sR augmenting its activity (Mackiewicz et al, 1995). The
combination of these agents has been shown to enhance the
cytostatic effects of IL-6 on T47D cells (Novick et al, 1992). By
demonstrating the presence of IL-6sR in breast primary cultures,
this may potentiate the interactive effects observed between IL-6
and E2.
When considered individually, E2 and IL-6 use different
signalling pathways, which seem to be unrelated. While E2 binds
to either ERa or ERb, both members of the steroid receptor super-
family, with subsequent transcription via EREs, Jaks and STAT
transcription factors mediate IL-6 signalling. However, the results
of this study have shown there are clearly interactive effects. This
complements a recent study in prostate cancer where another
member of the steroid receptor superfamily, the androgen receptor,
was also activated by IL-6 in reporter gene assays (Hobisch et al,
1998). Also in these assays, IL-6 showed synergistic activity with
glucocorticoid via activation of the IL-6 response element on a rat
a2-macroglobulin promoter (Takeda et al, 1998). This synergy
was enhanced by the exogenous expression of glucocorticoid
receptor, which parallels the results presented here; only cells
which were ERa+ showed increased transcriptional activity in
response to E2 and IL-6. An inhibition of protein kinase (PK) A,
PKC and MAP kinase pathways also down-regulated IL-6-
induced reporter gene activity (Hobisch et al, 1998), however,
inhibitors of PKC failed to block growth factor-dependent activa-
tion, suggesting multiple pathways for ligand-independent activa-
tion of ERa (Ignar-Trowbridge et al, 1996). Other examples of
ligand-independent activation of ERa include IL-2 and insulin-
like growth factor (IGF)-I (Newton et al, 1994a, 1994b).
The role of IL-6 as a modulator of reductive 17b-hydroxy-
steroid dehydrogenase type I activity in breast tumours has previ-
ously been shown (Speirs et al, 1993). Since this enzyme is
responsible for the production of E2, and as IL-6 can activate
ERa, an established prognostic marker in breast cancer on which
predictions to endocrine response and clinical outcome are based,
our results suggest that cross-talk between these signalling path-
ways may have clinical significance. This may be particularly rele-
vant in post-menopausal breast cancer patients where circulating
levels of E2 are reduced. In those patients, ERa transcription may
be activated by IL-6, which is known to be present in breast
tumours (Speirs et al, 1996b; Reed and Purohit, 1997).
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